Magnesium Treating Subarachnoid Hemorrhage Vasospasm

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

Also called NCT04613960

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 2/3
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04613960
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04613960. Randomized; quadruple masking; primary purpose prevention. Start 2022-12 (anticipated); primary completion 2023-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Magnesium Treating Subarachnoid Hemorrhage Vasospasm
Acronym
MATSH-SHapE
Condition
Subarachnoid Hemorrhage, Aneurysmal
Condition
Cerebral Vasospasm
Intervention (Drug)
Magnesium sulfate
Intervention (Drug)
normal saline
Lead sponsor
General Committee of Teaching Hospitals and Institutes, Egypt (class: other government)
Collaborator
Ain Shams University (class: other)
Collaborator
Health Insurance Organization, Egypt (class: not stated)

Record details

Record id
cardio:ct-nct04613960
Content hash
194358fd029dbf2edb37d53d15fc2340c293dd7cc4db3513ecc9af7abb37e8a6